Siveele B.V.

Bota Bio is a full-chain biotechnology company founded in September 2019, specializing in the research, development, and manufacturing of bio-enabled ingredients for the food, nutrition, and personal care industries. Operating under the mission to accelerate the global shift to bio-manufacturing, the company leverages its proprietary Biofoundry platform — an integrated system combining computer algorithms and advanced biotechnologies — to accelerate Design-Build-Test-Learn (DBTL) cycles and enable cleaner, more efficient biological manufacturing at scale.

The company operates two primary commercial brands: HeliaGenesis, focused on food and nutrition applications including bio-preservatives, nutritional supplements, and clean label ingredients; and Yucca Elements, dedicated to natural, high-efficiency synthetic biological materials for global personal care ingredient formulations and product development. Key products include Nisin, a commercially launched bio-preservative, and a growing pipeline of synthetic biology-derived ingredients for both sectors.

Bota Bio's manufacturing infrastructure includes a 130,000 square meter fermentation production plant with an annual output capacity exceeding 600 tons, purpose-built for the mass production of bio-preservatives and functional ingredients. The company also maintains six independent pilot plant production lines with a combined capacity of over 4,000 liters, bridging laboratory-scale R&D with full commercial manufacturing. Its strain engineering capabilities enable more than 1.5 million strains tested per year, while enzyme engineering operations process over 10,000 samples per day across 48 bioreactors.

With over 15 active R&D projects and a rapidly scaling organizational infrastructure, Bota Bio has built a comprehensive, ISO 9001:2015-certified quality management system and a digitalized, flexible supply chain network designed to support rapid R&D iteration in synthetic biology. The company completed a Series B funding round of over $100 million USD and a subsequent Series B+ round in June 2024, reflecting significant investor confidence in its technology platform and commercial trajectory.

Headquartered in China and led by CEO Dr. Cheryl Cui, Bota Bio has grown from its founding to revenues exceeding ¥100 million CNY by December 2023, with completed commercialization partnerships including a notable product commercialization collaboration with NHU in March 2024. The company serves global B2B markets, supplying ingredient manufacturers, CPG brands, and formulation developers across the food, nutrition, and personal care sectors seeking natural, bio-derived, and clean label alternatives to conventional synthetic chemicals.